Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 4/20 | 0.69 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.69 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.69 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008961 | 0.90 | OPRL1 (0.61) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL9963240 | 0.85 | GRIN2B (0.54) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL20147416 | 0.84 | OPRM1 (0.50) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL20147414 | 0.83 | OPRM1 (0.50) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL20147393 | 0.82 | OPRM1 (0.49) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL20147380 | 0.82 | OPRM1 (0.49) | OPRL1OPRM1OPRD1OPRK1CYP2D6 | |
| SCHEMBL20147389 | 0.81 | LMNA (0.51) | OPRL1OPRM1OPRD1OPRK1GRIN2B | |
| SCHEMBL156472 | 0.81 | OPRL1 (0.61) | OPRL1OPRM1OPRD1OPRK1GRIN2D | |
| SCHEMBL20147413 | 0.81 | MEN1 (0.69) | CYP2D6MEN1KMT2A | |
| SCHEMBL3582472 | 0.80 | MAOA (0.61) | OPRL1OPRM1OPRD1OPRK1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| WO-2023198597-A1 | RIFABUTIN ANALOGS FOR THE TREATMENT OF DISEASE | BioVersys AG (CH) | 2023-10-19 | — | — | WO | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-3661941-B1 | THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2022-12-14 | — | — | EP | disclosed |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2021-11-30 | — | — | US | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
| US-9034850-B2 | Gonadotropin releasing hormone receptor antagonist, preparation method thereof and pharmaceutical composition comprising the same | SK CHEMICALS CO., LTD. (KR) | 2015-05-19 | — | — | US | disclosed |
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | SK CHEMICALS CO. LTD. (KR) | 2013-05-30 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-8148404-B2 | Modulators of CB1 receptors | 7TM PHARMA A/S (DK) | 2012-04-03 | — | — | US | disclosed |
| WO-2011025690-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-03-03 | — | — | WO | disclosed |
| US-20100144701-A1 | Modulators of CB1 Receptors | 7TM PHARMA A/S (DK) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137661-A1 | Gonadotropin Releasing Hormone Receptor Antagonist, Preparation Method Thereof And Pharmaceutical Composition Comprising The Same | GNRHR, GHRHR, LHCGR | OPRL1 132/4885OPRM1 383/4885OPRD1 307/4885 |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | OPRL1 3532/4885OPRM1 2746/4885OPRD1 2173/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | OPRL1 2302/4885OPRM1 4093/4885OPRD1 4219/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | OPRL1 2144/4885OPRM1 4191/4885OPRD1 4225/4885 |
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | OPRL1 4643/4885OPRM1 4370/4885OPRD1 3732/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | OPRL1 3952/4885OPRM1 3497/4885OPRD1 2909/4885 |
| US-20100144701-A1 | Modulators of CB1 Receptors | CNR1, CNR2, GPR6 | OPRL1 23/4885OPRM1 81/4885OPRD1 78/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | OPRL1 4643/4885OPRM1 4370/4885OPRD1 3732/4885 |
| US-11186592-B2 | Thiazolopyridine derivatives as adenosine receptor antagonists | ADORA1, ADORA2A, AMPD2 | OPRL1 3044/4885OPRM1 3746/4885OPRD1 2562/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | OPRL1 4491/4885OPRM1 4147/4885OPRD1 3897/4885 |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | OPRL1 38/4885OPRM1 52/4885OPRD1 10/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | OPRL1 3547/4885OPRM1 2749/4885OPRD1 2196/4885 |
| US-20180134703-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | OPRL1 3952/4885OPRM1 3497/4885OPRD1 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.